

## Drug Patents Law in India

### What is the issue?

\n\n

India's rejection of secondary patents has kept blockbuster medicines affordable for many.

\n\n

### How are patents and drug pricing related?

\n\n

\n

- Patents offer their owners **market exclusivity** for a limited period of time.
- For medicines, this exclusivity should last as long as the **primary patent** is in effect, typically 20 years.
- Primary patent relates to the **active pharmaceutical ingredient (API)** of the medicine.
- The **end of patent exclusivity** is referred to as a patent cliff.
- This is because **drug prices fall** steeply by as much as 80% after the end of patent exclusivity.
- The price fall is driven by the **generic competition** that sets in.
- Resultantly, pharmaceutical companies witness **fall in profits**.

\n

\n\n

### What are secondary patents?

\n\n

\n

- Secondary patents are **claimed for derivatives and variants of the API**.
- This may include a physical variant of the API, a new formulation, a dosage

\n

regimen, or a new method of administering the medicine.

\n

- The pharmaceutical companies, who face losses, attempt to **postpone their patent exclusivity** by filing secondary patents.

\n

- The secondary patents prop up before the expiry of a primary patent.

\n

- It thereby **stretches the patent exclusivity** beyond 20 years.

\n

- This practice of extension of patent exclusivity is called “**evergreening**”.

\n

- The strategy is most lucrative when employed in the context of so-called **blockbuster medicines**.

\n

- These are medicines that reap annual revenues exceeding \$1 billion.

\n

\n\n

### **What is the recent Humira case?**

\n\n

\n

- Humira is one of the world’s best-selling prescription drug.

\n

- Its main ingredient is adalimumab which is a biologic used for the treatment of arthritis.

\n

- In 2015, Humira faced imminent expiry of patent of its main ingredient.

\n

- AbbVie Inc, makers of Humira, reassured its investors by citing the option of filing secondary patents which is allowed in the US.

\n

- Humira thus continues to grow even after the expiry of the patent over its main ingredient.

\n

- Over the years, AbbVie has increased the price of Humira in the U.S. by 100%, by steadily filing secondary patents.

\n

\n\n

### **What is the case with secondary patents in India?**

\n\n

\n

- The U.S. recognises and encourages secondary patents.  
\n
- India, however, does not encourage and has limitations in securing secondary patents.  
\n
- **Humira** - Indian Patent Office (IPO) had rejected Humira's secondary patents.  
\n
- Consequently, cheaper versions of the drug were introduced in India.  
\n
- Evidently, Humira costs Rs.85,000 in the U.S., and the same treatment costs only Rs.13,500 in India.  
\n
- **Other cases** - Another patent case worth mentioning is the Novartis' Glivec, a crucial leukaemia cure.  
\n
- The Supreme Court of India in 2013 upheld the rejection of a secondary patent for Novartis' Glivec.  
\n
- Likewise, Spiriva, a medicine for asthma, enjoys patent protection until 2021 in the U.S., largely due to secondary patents; rejected in India.  
\n

\n\n

### **How is the Indian patent law unique?**

\n\n

- As per the Patents Act, the product in question must feature a **technical advance** over what came before.  
\n
- Secondary patents for pharmaceuticals are often sought for trivial variants.  
\n
- They typically fail to qualify as an invention as prescribed in the Act.  
\n
- Further, when a medicine is merely a variant of a known substance, the Patents Act necessitates a **demonstration**.  
\n
- This is mandated in terms of showing the improvement in its **therapeutic efficacy**.  
\n
- The provision also bars patents for new uses and new properties of known substances.  
\n

- This additional requirement is unique to Indian law.  
\n
- Thus, to be deemed patentable, applications for secondary patents have to clear significant hurdles.  
\n
- The patent approval procedure ensures that bad patents stay out of the system.  
\n
- Indian patent law is thus commendable in preventing the evergreening practices by pharmaceutical companies.  
\n
- This is supportive in making affordable the blockbuster medicines which are crucial to the success of public health.  
\n

\n\n

\n\n

**Source: The Hindu**

\n

